OriginBrief
Pharma & Biotech·Week 3, November 2026·Generated November 15, 2026·20 sources·22 min read

Pharma & Biotech — November 16, 2026 Weekly

Pharma & Biotech news & updates — every claim linked to a primary source.

A public theme, built from 15 sources selected for it. Your reports come in this same format every week — from the sources you choose.

Key Findings

1

Executive Summary (4)

  • •The week's most consequential through-line is the simultaneous escalation of the AAV cancer risk story — from a single-company disclosure to a field-wide scientific consensus and formal regulatory retrospective — and China's sweeping biotech export restrictions and five-year plan designating biotech as a national pillar industry; together these two developments will reshape both the gene therapy development landscape and the geopolitical architecture of global biotech for years.
  • •The GLP-1 market entered a new phase of complexity: a new FDA safety warning on eye conditions, Eli Lilly's oral formulation showing sleep apnea benefits, and Pfizer securing $1.5 billion from Blackstone for its obesity program all arrived in the same week, signaling that the obesity drug race is simultaneously attracting more capital, expanding indications, and accumulating new safety obligations.
  • •European regulators delivered a high-volume, high-quality week — seven new EMA CHMP medicine recommendations including Gazyvaro for lupus, the MHRA's approval of retifanlimab and launch of an AI regulatory sandbox, and Merck receiving two positive CHMP opinions — contrasting sharply with the FDA's institutional turbulence: a shelved voucher program, a contested commissioner nomination, and a lung cancer rejection.
  • •The cardiovascular and commercial execution failures continued to accumulate — Alnylam's Amvuttra growth slowdown, Ionis's Tryngolza commercial miss, and ongoing post-AHA scrutiny of heart drug target validation — pointing to a systemic challenge in translating strong biology and regulatory approvals into durable commercial outcomes in cardiovascular medicine.
2

Key Points (17)

  • 1.STAT News confirmed on 2026-11-09 that gene therapy's long-debated cancer risk has materialized, with Nature Biotechnology publishing a comprehensive FDA CBER retrospective of AAV IND submissions from 1995 to 2025 on 2026-11-12 [15].
  • 2.China proposed to block the sale of 40 key biotech technologies to foreign entities including cell and gene therapy and siRNA, per Nature Biotechnology on 2026-11-10 [13].
  • 3.China's five-year plan designates biotechnology as a national pillar industry with a goal that at least 25% of all first-in-class drugs be developed domestically, per Nature Biotechnology on 2026-11-10 [14].
  • 4.BIO CEO John Crowley argued on 2026-11-10 that America's biotech sector supports nearly 10 million jobs and over $3 trillion in annual economic activity and that China's ambitions demand an urgent coordinated US response [20].
  • 5.The FDA warned GLP-1 drugmakers to add labeling for a potential risk of a rare eye condition, per STAT News on 2026-11-09 [18].
  • 6.Pfizer and Blackstone Life Sciences announced a strategic funding agreement of up to $1.5 billion for Pfizer's obesity program on 2026-11-11 [7].
  • 7.Beam Therapeutics announced its CRISPR-based sickle cell therapy risto-cel achieved the primary goal of a pivotal trial and plans to file an FDA marketing application as soon as year end, per STAT News on 2026-11-10 [18].
  • 8.The EMA CHMP recommended seven new medicines and 11 indication extensions at its November 9-12 meeting, including Gazyvaro for systemic lupus erythematosus [4].
  • 9.The MHRA approved retifanlimab (ZYNYZ) for anal cancer on 2026-11-11 and launched the AI Airlock regulatory sandbox for AI-enabled medical devices on 2026-11-10 [11].
  • 10.Merck received positive EU CHMP opinions for ENFLONSIA expansion to children up to 24 months and for WELIREG in combination with lenvatinib for advanced renal cell carcinoma on 2026-11-13 [3].
  • 11.Merck announced positive Phase 2b results for efinopegdutide in adults with MASH and Stage 2-3 fibrosis on 2026-11-09 [3].
  • 12.J&J showcased hematology data at ASH 2026 on 2026-11-10 including Phase 3 data for TECVAYLI plus TALVEY and first results from ramantamig trispecific antibody [10].
  • 13.Ionis Pharmaceuticals lost more than $1 billion in market value after slashing Tryngolza sales projections to $50 million from a prior forecast of $100 to $110 million, with Q3 sales of $9 million against Wall Street expectations of $21 million [16].
  • 14.The FDA rejected Summit Therapeutics' lung cancer treatment ivonescimab on 2026-11-15 [2].
  • 15.The FDA shelved the Commissioner's National Priority Voucher program and Heidi Overton's FDA nomination faces a tight Senate committee vote, per STAT News on 2026-11-12 [19].
  • 16.IFPMA welcomed the B20 Leaders' Statement recognizing healthcare innovation as a key priority for economic growth on 2026-11-12 and published a position paper on AI in regulatory activities on 2026-11-09 [12].
  • 17.PMDA faced dual IT disruptions — the ongoing DWAP suspension and a new Microsoft Outlook outage on 2026-11-13 — while continuing to publish safety notices and new pediatric drug development Q&A guidance [5].
3

Market Trends

AAV Cancer Risk Escalates from Signal to Confirmed Field-Wide Threat

The AAV oncogenicity story continued to deepen this week. STAT News reported on 2026-11-09 that gene therapy's long-debated cancer risk has now 'materialized,' with the Readout newsletter framing it as a settled scientific question [17]. Nature Biotechnology published on 2026-11-12 a comprehensive analysis of FDA CBER experience with AAV gene therapy IND submissions from 1995 to 2025, highlighting rapid growth in AAV development and common reasons for regulatory holds [15]. The pattern this week…

GLP-1 Market Expands and Fragments as New Safety Signals and Formulations Emerge

The GLP-1 landscape shifted on multiple fronts this week. The FDA warned GLP-1 drugmakers to add labeling for a potential risk of a rare eye condition, according to STAT News on 2026-11-09 [18]. Eli Lilly's GLP-1 pill Foundayo showed it helped alleviate sleep apnea in studies, per STAT News on 2026-11-09 [2]. Pfizer and Blackstone Life Sciences announced a strategic funding agreement for Pfizer's obesity program on 2026-11-11, with Blackstone committing up to $1.5 billion for R&D of Pfizer's GLP…

US-China Biotech Rivalry Intensifies as China Designates Biotech a National Pillar Industry

China's strategic ambitions in biotechnology crystallized this week. Nature Biotechnology reported on 2026-11-10 that China's latest five-year plan designates biotechnology as a national 'pillar industry' and includes an objective that at least 25% of all first-in-class drugs be developed domestically, with goals including 50 domestic drugmakers having at least $1.5 billion in annual sales and five products being blockbusters globally [14]. Separately, Nature Biotechnology reported on 2026-11-10…

Drug Pricing Pressure Mounts as Most-Favored-Nation Policy Forces Launch Rethinks

The Trump administration's most-favored-nation drug pricing policy is now materially affecting commercial strategy. STAT News reported on 2026-11-11 that the MFN policy is making drugmakers rethink launches abroad, with a former Eli Lilly sales rep also filing a lawsuit alleging she was fired after complaining that the company promoted Mounjaro as a weight loss treatment before receiving regulatory approval [2a]. Ionis Pharmaceuticals lost more than $1 billion in market value after slashing sale…

Cardiovascular Drug Failures Persist, Raising Structural Questions About Target Validation

The cardiovascular failure trend from the prior week continued. STAT News reported on 2026-11-13 that the future of heart drug research is under scrutiny in the wake of study setbacks [2]. Alnylam's stock has tumbled as sales growth for its cardiomyopathy treatment Amvuttra slowed, with STAT News reporting on 2026-11-12 that the company needs to solve its heart drug problem [2b]. The pattern of cardiovascular failures — spanning Novartis, Novo Nordisk, and now Alnylam's commercial struggles — po…

4

Competitor Trends

J&J Expands Oncology and Hematology Pipeline with Multiple Data Readouts at ASH and ACR

J&J continued its multi-indication expansion strategy this week. On 2026-11-10, J&J showcased hematology data at ASH 2026, including Phase 3 data for TECVAYLI plus TALVEY demonstrating reduced risk of disease progression in relapsed or refractory multiple myeloma, first results from ramantamig (an investigational trispecific antibody), positive Phase 2 results for bleximenib in AML, and first data for a novel CALRmut × CD3 T-cell engaging antibody in essential thrombocythemia [10] (company annou…

Pfizer Secures $1.5 Billion Blackstone Funding for Obesity Program, Signaling Commitment to GLP-1 Race

Pfizer and Blackstone Life Sciences announced a strategic funding agreement on 2026-11-11 for Pfizer's obesity program, with Blackstone committing up to $1.5 billion for R&D of Pfizer's GLP-1 candidate [7] (company announcement — may reflect promotional framing). STAT News reported on 2026-11-12 that Blackstone backs Pfizer's bet on a monthly obesity treatment [19]. This deal signals that Pfizer is not ceding the obesity market to Lilly and Novo Nordisk, and that institutional capital is willing…

Merck Receives Positive EU CHMP Opinions for ENFLONSIA and WELIREG Expansions

Merck received two positive EU CHMP opinions on 2026-11-13: one to expand ENFLONSIA (clesrovimab) marketing authorization to include children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season, and one for WELIREG (belzutifan) in combination with lenvatinib for adults with advanced renal cell carcinoma following treatment with an anti-PD-1/PD-L1 therapy [3] (company announcement — may reflect promotional framing). Merck also announced positive Phas…

Bristol Myers Squibb Restructures R&D Leadership Ahead of Patent Cliff

Bristol Myers Squibb made changes to its R&D structure, with Chief Medical Officer Cristian Massacesi given the additional title of head of R&D, while research chief Robert Plenge will depart the company in March, according to STAT News on 2026-11-12 [19]. Endpoints News reported on 2026-11-12 that Bristol Myers is shaking up R&D leadership ahead of its patent cliff [8]. This consolidation of R&D leadership under a single executive signals BMS is prioritizing execution efficiency as it faces the…

Beam Therapeutics CRISPR Sickle Cell Therapy Achieves Pivotal Trial Primary Goal

Beam Therapeutics announced on 2026-11-10 that its CRISPR-based treatment for sickle cell disease, called risto-cel, achieved the primary goal of a pivotal clinical trial — freedom from severe pain crises for at least 12 months — and said it would file an FDA marketing application as soon as the end of this year, according to STAT News [18]. This is a significant milestone for base editing as a therapeutic modality and positions Beam as a near-term competitor in the gene therapy space for hemogl…

5

Regulatory Trends

EMA CHMP Recommends Seven New Medicines Including Gazyvaro for Lupus

The EMA published meeting highlights from the CHMP for its November 9-12, 2026 meeting on 2026-11-13, recommending seven new medicines for approval and 11 medicines for extension of therapeutic indications [4]. The EMA separately recommended extending Gazyvaro's use to systemic lupus erythematosus, noting it reduces disease activity and use of corticosteroids [4]. This is a notable expansion of Gazyvaro's indication beyond its prior oncology use and reflects the EMA's continued active approval c…

MHRA Approves Retifanlimab for Anal Cancer and Launches AI Regulatory Sandbox

The MHRA approved retifanlimab (ZYNYZ) for the treatment of adults with squamous cell carcinoma of the anal canal on 2026-11-11 [11]. The MHRA also launched the 'AI Airlock,' described as a regulatory sandbox for AI-enabled medical devices, on 2026-11-10 [11]. Additionally, investigational treatments for lung cancer, Huntington's disease, and Alzheimer's gained Innovation Passports through the Innovative Licensing and Access Pathway on 2026-11-09 [11]. The MHRA is simultaneously advancing approv…

IFPMA Welcomes B20 Recognition of Healthcare Innovation as Economic Growth Driver

IFPMA issued a statement on 2026-11-12 welcoming the Business20 Leaders' Statement and its recognition of long-term investment in R&D and healthcare innovation as key priorities for economic growth and prosperity, following the B20 USA Summit in Washington [12] (company announcement — may reflect promotional framing). IFPMA called on business and government leaders to keep health innovation at the heart of B7 and B20 agendas and to translate business consensus into G7 and G20 action. IFPMA also …

PMDA Faces Dual IT Disruptions as Regulatory Operations Continue

Japan's PMDA continued to operate under two simultaneous IT disruptions this week. The DWAP medical device web application platform remains suspended following the October cybersecurity incident, with no restart date confirmed [5]. On 2026-11-13, PMDA also reported a Microsoft Outlook email system outage affecting its ability to receive inquiries and process procedures, with deadline extensions and alternative contact methods announced [5]. Despite these disruptions, PMDA published new safety no…

FDA Rejects Ivonescimab in Lung Cancer as Heidi Overton FDA Nomination Faces Uncertain Vote

The FDA rejected Summit Therapeutics' lung cancer treatment ivonescimab on 2026-11-15, according to STAT News [2]. Separately, STAT News reported on 2026-11-12 that the Senate health committee will vote the following Wednesday on Heidi Overton's nomination to lead the FDA, with Committee Chair Bill Cassidy describing her role in shaping vaccine policies as 'almost disqualifying,' and a single Republican defection potentially sinking the nomination [19]. The FDA also shelved the Commissioner's Na…

Sources Activity

6

Since last week

AAV Cancer Risk Confirmed and Escalating: FDA Investigation Active, Nature Biotechnology Publishes IND Retrospective

VerifiedUpdated

Building on last week's Zolgensma tumor disclosures and FDA investigation launch, this week STAT News confirmed gene therapy's long-debated cancer risk has 'materialized' [17]. Nature Biotechnology published a comprehensive FDA CBER analysis of AAV gene therapy IND submissions from 1995 to 2025, highlighting rapid growth and common regulatory hold reasons [15]. The story has evolved from a single company disclosure to a field-wide regulatory and scientific reckoning.

Related: Market TrendsSource: STAT News – Gene Therapy Cancer Risk Materializes, Nature Biotechnology – FDA CBER AAV IND Analysis

China Biotech Export Ban Proposed and Five-Year Plan Designates Biotech as Pillar Industry

VerifiedNew

Nature Biotechnology reported on 2026-11-10 that China proposed to block the sale of certain biotech platforms to foreign entities, adding 40 key technologies including cell and gene therapy and siRNA to an export blacklist [13]. China's five-year plan also designates biotechnology as a national pillar industry with ambitious domestic development targets [14]. The BIO CEO called for a coordinated US response, describing the competition as a modern Space Race [20].

Related: Market TrendsSource: Nature Biotechnology – China Biotech Export Ban, Nature Biotechnology – China Five-Year Plan Biotech Objectives, STAT News – China Biotech Space Race Op-Ed

FDA Issues GLP-1 Eye Condition Warning and Pfizer Secures $1.5B Blackstone Obesity Funding

VerifiedNew

The FDA warned GLP-1 drugmakers to add labeling for a potential risk of a rare eye condition, per STAT News on 2026-11-09 [18]. Pfizer and Blackstone announced a strategic funding agreement of up to $1.5 billion for Pfizer's obesity program on 2026-11-11 [7]. These two developments together illustrate the GLP-1 market simultaneously facing new safety scrutiny and attracting major new capital commitments.

Related: Competitor TrendsSource: STAT News – GLP-1 FDA Eye Condition Warning, Pfizer Press Releases

EMA CHMP Recommends Seven New Medicines; MHRA Approves Retifanlimab and Launches AI Sandbox

VerifiedNew

The EMA CHMP recommended seven new medicines and 11 indication extensions at its November 9-12 meeting, including Gazyvaro for systemic lupus erythematosus [4]. The MHRA approved retifanlimab (ZYNYZ) for anal cancer on 2026-11-11 and launched the AI Airlock regulatory sandbox for AI-enabled medical devices on 2026-11-10 [11]. These represent a high-volume approval and innovation infrastructure week for European regulators.

Related: Regulatory TrendsSource: EMA News, MHRA – Medicines and Healthcare products Regulatory Agency (UK)

FDA Leadership Uncertainty Deepens: Overton Nomination at Risk, Voucher Program Shelved

VerifiedNew

STAT News reported on 2026-11-12 that the Senate health committee vote on Heidi Overton's FDA nomination faces a tight outcome, with Committee Chair Cassidy calling her vaccine policy role 'almost disqualifying' [19]. The FDA also shelved the Commissioner's National Priority Voucher program [19]. The FDA rejected ivonescimab in lung cancer on 2026-11-15 [2]. These developments collectively signal continued institutional instability at the FDA.

Related: Regulatory TrendsSource: STAT News – Blackstone Pfizer Obesity Deal, STAT News
7

Watchlist — Upcoming Deadlines

2026-11-19

Senate health committee vote on Heidi Overton's nomination to lead the FDA (scheduled for the Wednesday following 2026-11-12 report)

Source: STAT News – Blackstone Pfizer Obesity Deal
2026-11-26

IHI EFPIA event: How to predict who will respond best to different treatments for obesity (SOPHIA project insights)

Source: EFPIA
2026-12-03

EFPIA/J&J event: Signal over noise — what will make AI stick in pharma R&D

Source: EFPIA
8

Strategic Insights (10)

  • 1.The Nature Biotechnology FDA CBER retrospective on AAV IND submissions published this week is the most authoritative public document yet on what causes regulatory holds in gene therapy — companies with active AAV programs should treat it as a compliance checklist, not just background reading.
  • 2.China's proposed biotech export ban covering cell and gene therapy and siRNA technologies, combined with its five-year plan to develop 25% of first-in-class drugs domestically, creates a structural bifurcation: licensing deals for Chinese-originated assets may become harder to execute even as China's domestic pipeline grows, compressing the window for Western companies to access Chinese innovation.
  • 3.The FDA's GLP-1 eye condition warning is the first major safety label update for the class since widespread adoption — it will likely trigger a wave of pharmacovigilance reviews across all GLP-1 programs and may affect prescribing patterns in patients with pre-existing ophthalmologic conditions.
  • 4.Pfizer's $1.5 billion Blackstone deal for its monthly obesity candidate is a strategic signal that Pfizer is betting on dosing differentiation (monthly versus weekly) as its path to market share — if the monthly formulation succeeds, it could redefine patient preference and adherence benchmarks for the entire GLP-1 class.
  • 5.Beam Therapeutics' pivotal trial success for risto-cel in sickle cell disease, with a planned year-end FDA filing, will be one of the first major base editing regulatory submissions — its review will be closely watched as a precedent for how the FDA evaluates base editing versus traditional CRISPR approaches in the context of the active AAV safety investigation.
  • 6.The MHRA's AI Airlock sandbox launch this week, combined with IFPMA's position paper on AI in regulatory activities and PMDA's earlier Early Consideration document, signals that all three major regulatory jurisdictions are now actively building AI governance frameworks — companies using AI in drug development should expect formal guidance requirements within 12-24 months.
  • 7.Ionis's Tryngolza commercial miss — Q3 sales of $9 million against $21 million consensus, with a full-year forecast cut from $100-110 million to $50 million — illustrates that physician adoption of novel mechanisms in established therapeutic areas (triglyceride lowering) can be far slower than financial models assume, even with strong clinical data.
  • 8.Bristol Myers Squibb's R&D leadership consolidation under a single executive ahead of its patent cliff is a structural efficiency move, but the departure of research chief Robert Plenge in March removes a key scientific voice at a moment when BMS needs to identify its next generation of assets — the timing creates execution risk.
  • 9.The EMA's recommendation of Gazyvaro for systemic lupus erythematosus represents a meaningful indication expansion for obinutuzumab beyond oncology, and signals that anti-CD20 mechanisms have broader autoimmune applicability than previously approved — a competitive signal for other companies developing CD20-targeting agents in autoimmune disease.
  • 10.The FDA's shelving of the Commissioner's National Priority Voucher program, combined with the contested Overton nomination, suggests the FDA is entering a period of reduced programmatic innovation — companies that had planned to use vouchers as a financing mechanism for rare disease programs will need to revise their capital strategies.

Trust Summary

20 sources cited this week

Detected across 15 monitored URLs selected for this public theme — one URL can surface multiple articles. In your own themes, these are the URLs you choose.

Each source is weighted by its trust level. Single-source claims are flagged as unverified during AI synthesis.

9

Sources

[1]Industry

IFPMA welcomed the B20 Leaders' Statement recognizing healthcare innovation as a key economic priority on 2026-11-12. Published position paper on AI in regulatory activities on 2026-11-09. Published expert insights on influenza vaccination coverage value on 2026-11-11.

Related: Regulatory TrendsVerified
[2]Media
STAT News2026-11-15

STAT News reporting covering AAV cancer risk materialization (2026-11-09), FDA GLP-1 eye condition warning (2026-11-09), Ionis Tryngolza commercial miss (2026-11-09), Bayer stroke drug FDA approval (2026-11-09), Beam sickle cell pivotal success (2026-11-10), China biotech Space Race op-ed (2026-11-10), MFN policy launch rethinks (2026-11-11), Alnylam heart drug growth problems (2026-11-12), Blackstone-Pfizer obesity deal (2026-11-12), FDA voucher program shelved and Overton nomination tight vote (2026-11-12), HHS ibogaine funding (2026-11-13), FDA ivonescimab rejection (2026-11-15).

Related: Market TrendsVerified
[3]Corporate
Merck Newsroom2026-11-13

Merck announced positive Phase 2b results for efinopegdutide in MASH on 2026-11-09. Received positive EU CHMP opinions for ENFLONSIA expansion to children up to 24 months and WELIREG in combination with lenvatinib for advanced renal cell carcinoma on 2026-11-13.

Related: Competitor TrendsVerified
[4]Government & Intl
EMA News2026-11-13

EMA published CHMP meeting highlights for November 9-12, 2026, recommending seven new medicines and 11 indication extensions. EMA separately recommended extending Gazyvaro's use to systemic lupus erythematosus on 2026-11-13.

Related: Regulatory TrendsVerified
[5]Government & Intl
PMDA (Japan)2026-11-14

PMDA continued operating under DWAP suspension and new Microsoft Outlook outage from 2026-11-13. Published nitrosamine detection notice for sertraline and telmisartan tablets on 2026-11-10, Class I recall of irradiated red blood cells on 2026-11-09, new optimal use guidelines on 2026-11-12, and pediatric drug development Q&A on 2026-11-13.

Related: Regulatory TrendsVerified
[6]Industry
EFPIA2026-11-13

EFPIA published blog on pharmaceutical sector green transition on 2026-11-09, noting renewable electricity consumption among surveyed EFPIA member companies has tripled in five years and 90% of companies align targets to SBTi guidelines. Upcoming events include IHI obesity treatment prediction event on 2026-11-26 and AI in pharma R&D event on 2026-12-03.

Related: Regulatory TrendsVerified
[7]Corporate

Pfizer and Blackstone Life Sciences announced strategic funding agreement of up to $1.5 billion for Pfizer's obesity program on 2026-11-11.

Related: Competitor TrendsVerified
[8]Media
Endpoints News2026-11-15

Endpoints News reporting on Bayer FDA approval for stroke prevention drug (2026-11-10), FDA GLP-1 eye disease warning (2026-11-12), Bristol Myers R&D leadership restructuring (2026-11-12), Blackstone $1.5B Pfizer GLP-1 deal (2026-11-12), FDA voucher program shelved (2026-11-13), FDA ivonescimab rejection (2026-11-15), Moderna readying commercial cancer vaccine production (2026-11-13).

Related: Competitor TrendsConfirmed by 103 other sources
[9]Academic

Nature Biotechnology November 2026 issue published on 2026-11-10 with focus on climate biotech. Published news on China biotech export ban proposal (2026-11-10), China five-year plan biotech objectives (2026-11-10), AI tech giants in drug discovery (2026-11-10), and comprehensive FDA CBER analysis of AAV gene therapy IND submissions 1995-2025 (2026-11-12).

Related: Market TrendsVerified
[10]Corporate
J&J Newsroom2026-11-14

J&J announced ASH 2026 hematology data including TECVAYLI plus TALVEY Phase 3 results, ramantamig trispecific antibody first results, bleximenib Phase 2 AML results, and CALRmut T-cell engaging antibody data on 2026-11-10. J&J announced CAPLYTA second positive Phase 3 study in bipolar mania on 2026-11-10. J&J reported 73% PSA response rate with pasritamig combination in prostate cancer on 2026-11-09.

Related: Competitor TrendsVerified
[11]Government & Intl

MHRA approved retifanlimab (ZYNYZ) for anal cancer on 2026-11-11. Launched AI Airlock regulatory sandbox for AI-enabled medical devices on 2026-11-10. Investigational treatments for lung cancer, Huntington's disease, and Alzheimer's gained Innovation Passports on 2026-11-09. Class 4 medicines defect notification for Star Pharmaceuticals enalapril/hydrochlorothiazide labeling error on 2026-11-12. Microsoft outage affecting services noted on 2026-11-13.

Related: Regulatory TrendsVerified
[12]Industry

IFPMA statement welcoming B20 Leaders' Statement recognition of long-term R&D investment and healthcare innovation as key priorities for economic growth, following B20 USA Summit in Washington. Calls on leaders to keep health innovation at heart of B7 and B20 agendas and translate consensus into G7 and G20 action.

Related: Regulatory TrendsVerified
[13]Academic

Nature Biotechnology reported China's government proposed to block the sale of certain biotech platforms to foreign entities, adding 40 key technologies to the export blacklist including five technologies related to pathogen gain-of-function platforms, cell and gene therapy, and small interfering RNA.

Related: Market TrendsVerified
[14]Academic

Nature Biotechnology reported China's latest five-year plan includes development of at least 25% of all first-in-class drugs as one of ten objectives, with goals including 50 domestic drugmakers having at least $1.5 billion in annual sales and five products being blockbusters globally.

Related: Market TrendsVerified
[15]Academic

Nature Biotechnology published comprehensive analysis of FDA CBER experience with AAV gene therapy IND submissions from 1995 to 2025, revealing rapid growth in AAV development over three decades and highlighting common reasons for regulatory holds.

Related: Market TrendsVerified
[16]Media

Ionis Pharmaceuticals lost more than $1 billion in market value after slashing Tryngolza sales projections to $50 million from $100-110 million, with Q3 sales of $9 million against Wall Street expectations of $21 million. Shares dropped approximately 25% from above $39 to below $28.

Related: Market TrendsVerified
[17]Media

STAT News Readout newsletter confirmed gene therapy's long-debated cancer risk has materialized, covering Vir Biotechnology hepatitis D Phase 3 success, Zura Bio hidradenitis suppurativa failure, Roivant Lisraya $31 million in five-week sales, and Argenx acquisition of Unnatural Products.

Related: Market TrendsVerified
[18]Media

STAT News reported FDA warned GLP-1 drugmakers to update product labels to reflect increased risk of a rare eye condition. Also reported Beam Therapeutics sickle cell therapy risto-cel achieved primary goal of pivotal trial with planned year-end FDA marketing application filing.

Related: Regulatory TrendsVerified
[19]Media

STAT News reported Blackstone backs Pfizer's bet on monthly obesity treatment. Also reported Bristol Myers Squibb R&D restructuring with Massacesi taking head of R&D title and Plenge departing in March, FDA shelving Commissioner's National Priority Voucher program, and Heidi Overton FDA nomination facing tight Senate committee vote.

Related: Competitor TrendsVerified
[20]Media

BIO CEO John Crowley op-ed arguing America's biotech sector supports nearly 10 million jobs and over $3 trillion in annual economic activity, and that China's new five-year plan designating biotech as a national pillar industry demands an urgent coordinated US response.

Related: Market TrendsVerified

Your sources, turned into a report like this every week

Pick the sources you follow — a regulator's bulletins, your competitors' newsrooms, the research you read — and OriginBrief turns what changed in them into a cited report like this one, every week. It reads only the sources you add. 7-day free trial — plans from $33/mo.

Start your 7-day free trial

Related Reports

From other themes

Track your own themes with OriginBrief

Start 7-day free trial →